OnNovember 7th, during the 5th China International Import Expo, Ping An Health Insurance, Roche, and OrigiMed announced a strategic cooperation to launch an innovative payment service program for Chinese pan-tumor targets, aiming to help Chinese NTRK-positive patients lower their healthcare costs.
On September 22, 2022, Menarini, an Italian biopharmaceutical company, and OrigiMed, a leading Chinese precision medicine company, announced their strategic cooperation to jointly launch an innovative platform for pan-cancer single-cell precision.
Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide.
OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. ("Janssen").
OrigiMed announced that the Human NTRK1/2/3 Genomic Alteration Testing Kit has been granted the Special Review Procedure for Innovative Medical Devices by the Center for Medical Device Evaluation of NMPA.
5th Floor, Building 3, 115 Xinjun Ring Road, Minhang District, Shanghai
Floor 4, Information Building 2, Zhaolou Road 3576 , Pujiang Town, Minhang District, Shanghai
400-821-9890
Service Hours:9:00-18:00 Monday to Friday (except statutory holidays)
zbservice@origimed.com
We will reply you as soon as we receive the email.
All rights reserved in © Copyright 2022 OrigiMed Ltd
Registration Number:沪ICP备16027109号-1